Published in J Virol on May 01, 1997
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol (2001) 8.25
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol (2008) 3.83
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol (2009) 3.36
Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol (2001) 2.79
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34
Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol (2009) 2.16
Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol (2008) 2.16
A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol (1999) 2.12
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol (2002) 1.97
Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J Virol (2009) 1.88
Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A (2003) 1.88
Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol (2003) 1.84
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol (2009) 1.78
Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J Virol (2005) 1.70
The Antibody Response against HIV-1. Cold Spring Harb Perspect Med (2012) 1.65
Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog (2013) 1.65
Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol (2006) 1.65
Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J Virol (1999) 1.55
Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol (2002) 1.54
Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. J Virol (2001) 1.53
Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys. J Virol (1998) 1.49
Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol (2004) 1.49
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol (2008) 1.44
Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol (2001) 1.42
Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol (1998) 1.39
Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections. J Virol (1998) 1.38
Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J Virol (2001) 1.35
Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. J Virol (2004) 1.32
Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate. J Virol (2000) 1.30
Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J Virol (2001) 1.25
Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. J Virol (2002) 1.25
Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. Curr Opin HIV AIDS (2007) 1.24
Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J Virol (2001) 1.09
Correlation of acute humoral response with brain virus burden and survival time in pig-tailed macaques infected with the neurovirulent simian immunodeficiency virus SIVsmmFGb. Am J Pathol (2004) 1.05
epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals. J Virol (2011) 1.04
Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques. J Virol (2001) 1.02
Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes. J Virol (2000) 1.01
Nonpathogenic simian immunodeficiency virus infection of sooty mangabeys is not associated with high levels of autologous neutralizing antibodies. J Virol (2010) 1.01
Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity. J Virol (2005) 1.01
Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J Virol (2011) 1.00
Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope. J Virol (2004) 0.99
Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. J Virol (1998) 0.97
Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition. J Virol (2001) 0.97
Which Antibody Functions are Important for an HIV Vaccine? Front Immunol (2014) 0.94
Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection. Retrovirology (2010) 0.91
The humoral response to HIV-1: new insights, renewed focus. J Infect Dis (2010) 0.91
Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine. Retrovirology (2006) 0.90
Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes. PLoS One (2010) 0.89
Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology (2011) 0.85
Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic. PLoS Pathog (2013) 0.83
Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge. PLoS One (2011) 0.83
Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development. Adv Virol (2012) 0.82
Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques. Vaccines (Basel) (2013) 0.81
Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees. J Virol (2000) 0.81
Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes. J Virol (2014) 0.81
Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy. PLoS Pathog (2010) 0.80
Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog (2017) 0.79
Phenotypic Correlates of HIV-1 Macrophage Tropism. J Virol (2015) 0.79
Autologous neutralizing antibody to human immunodeficiency virus-1 and replication-competent virus recovered from CD4+ T-cell reservoirs in pediatric HIV-1-infected patients on HAART. AIDS Res Hum Retroviruses (2010) 0.78
Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes. J Allergy Clin Immunol (2012) 0.78
Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies. Retrovirology (2009) 0.78
Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein. J Immunol (2014) 0.78
Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production. Sci Rep (2014) 0.77
Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India. AIDS Res Hum Retroviruses (2008) 0.77
An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virus. J Gen Virol (2014) 0.76
Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization. PLoS One (2012) 0.76
Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and Denmark. AIDS Res Hum Retroviruses (2016) 0.75
Natural infection as a blueprint for rational HIV vaccine design. Hum Vaccin Immunother (2016) 0.75
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med (1995) 8.23
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A (1988) 7.74
Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature (1985) 6.65
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A (1989) 6.58
Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol (1993) 6.41
HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature (1985) 5.10
Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol (1995) 5.01
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med (1995) 4.28
Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies? Lancet (1992) 4.05
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol (1993) 3.95
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol (1994) 3.70
Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol (1996) 3.48
Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol (1994) 3.28
Follicular dendritic cells and human immunodeficiency virus infectivity. Nature (1995) 3.22
HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS (1995) 3.08
Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis (1996) 2.84
Neutralization of HIV-1. AIDS Res Hum Retroviruses (1994) 2.65
HIV-1 subtype and second-receptor use. Nature (1996) 2.46
Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis (1994) 2.42
Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis. Lancet (1987) 2.34
V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol (1993) 2.27
Specific cytotoxic T cells eliminate B cells producing virus-neutralizing antibodies [corrected]. Nature (1996) 2.25
Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol (1995) 2.24
Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis (1993) 1.86
Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses (1995) 1.72
Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis (1995) 1.65
Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr (1994) 1.57
Comparative studies on use of fresh and frozen peripheral blood lymphocyte specimens for isolation of human immunodeficiency virus and effects of cell lysis on isolation efficiency. J Clin Microbiol (1987) 1.47
Jitters jeopardize AIDS vaccine trials. Science (1993) 1.44
Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol (1996) 1.41
Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J Virol (1994) 1.41
Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J Virol (1996) 1.40
Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. Lancet (1994) 1.40
Development of HIV-1 group-specific neutralizing antibodies after seroconversion. AIDS (1992) 1.39
Effect of different donor cells on human immunodeficiency virus type 1 replication and selection in vitro. J Virol (1995) 1.35
Antibody neutralization of HIV-1. Immunol Today (1996) 1.29
Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.25
Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. Virology (1994) 1.25
Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. J Virol (1996) 1.22
The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. J Immunol (1994) 1.21
Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology (1993) 1.11
Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. J Virol (1994) 1.10
A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. AIDS Res Hum Retroviruses (1995) 1.10
A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J Virol (1994) 1.08
Can the immune response control HIV infection? Cell (1995) 1.07
Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion. J Infect Dis (1994) 1.02
Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro. AIDS Res Hum Retroviruses (1997) 1.01
Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain. AIDS Res Hum Retroviruses (1994) 0.98
Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS. Immunol Lett (1996) 0.93
Autologous antibody response against the principal neutralizing domain of human immunodeficiency virus type 1 isolated from infected humans. J Virol (1993) 0.92
Analysis of B cell repertoire specific to the neutralizing epitopes of glycoprotein 120 in HIV-infected individuals. AIDS Res Hum Retroviruses (1994) 0.90
Intrapatient variability of the human immunodeficiency virus type 2 envelope V3 loop. AIDS Res Hum Retroviruses (1995) 0.86
Bicyclic imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1. Antiviral Res (1994) 0.85
Sequence variation within the human immunodeficiency virus V3 loop at seroconversion. J Med Virol (1993) 0.83
Autologous neutralizing antibodies and viral load in HIV-2-infected individuals. AIDS (1995) 0.82
The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies. Arch Virol (1995) 0.79
A radiation hybrid map of the zebrafish genome. Nat Genet (1999) 2.31
Creatine kinase-BB: a marker of liver sinusoidal damage in ischemia-reperfusion. Hepatology (1993) 2.23
Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc Natl Acad Sci U S A (1994) 2.21
High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS (1995) 1.93
Host range deletion mutant of vaccinia virus defective in human cells. Virology (1981) 1.81
Assembly of nucleocapsidlike structures in animal cells infected with a vaccinia virus recombinant encoding the measles virus nucleoprotein. J Virol (1991) 1.73
Localization and sequence of a vaccinia virus gene required for multiplication in human cells. Proc Natl Acad Sci U S A (1986) 1.62
Hepatitis C virus genotyping based on 5' noncoding sequence analysis (Trugene). J Clin Microbiol (2001) 1.56
Complementation and genetic linkage between vaccinia virus temperature-sensitive mutants. Virology (1982) 1.45
Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob Agents Chemother (1994) 1.43
Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein. Proc Natl Acad Sci U S A (1988) 1.43
Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis (1998) 1.39
Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest (1994) 1.39
A cowpox virus gene required for multiplication in Chinese hamster ovary cells. J Virol (1988) 1.31
Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques. J Immunol (1992) 1.27
Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.25
Primary cultures of endothelial cells from the human liver sinusoid are permissive for human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.21
A hospital outbreak of gastroenteritis possibly related to the contamination of tap water by a small round structured virus. J Hosp Infect (1999) 1.17
Host range restriction of vaccinia virus in Chinese hamster ovary cells: relationship to shutoff of protein synthesis. J Virol (1978) 1.17
1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein. C R Acad Sci III (2000) 1.16
Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J Clin Microbiol (1997) 1.14
A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. J Med Chem (1995) 1.14
Phagocytosis, an unrecognized property of murine endothelial liver cells. Hepatology (1986) 1.14
Infection of primary cultures of human Kupffer cells by Dengue virus: no viral progeny synthesis, but cytokine production is evident. J Virol (1999) 1.14
Limited viral spread and rapid immune response in lymph nodes of macaques inoculated with attenuated simian immunodeficiency virus. Virology (1995) 1.13
Interaction of viruses with sinusoidal cells. Prog Liver Dis (1982) 1.10
Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res (1994) 1.10
Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase. J Med Chem (2000) 1.09
Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy. J Clin Microbiol (1998) 1.08
Increase in the number of fenestrae in mouse endothelial liver cells by altering the cytoskeleton with cytochalasin B. Hepatology (1988) 1.08
Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1. AIDS Res Hum Retroviruses (1997) 1.07
In vitro infection of peripheral blood mononuclear cells by hepatitis C virus. J Gen Virol (1995) 1.06
Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3'-azido-2',3'-dideoxythymidine 5'-monophosphate. J Med Chem (1995) 1.04
Human immunodeficiency virus type 1 infection of human CD4-transgenic rabbits. J Gen Virol (1995) 1.03
Study of human herpesvirus 8 (HHV-8) variants from Kaposi's sarcoma in France: is HHV-8 subtype A responsible for more agressive tumors? J Infect Dis (1998) 1.03
Virus-associated nucleases: evidence for endonuclease and exonuclease activity in rabbitpox and vaccinia viruses. J Virol (1972) 1.03
Cell biology and kinetics of Kupffer cells in the liver. Int Rev Cytol (1989) 1.03
Detection of JC virus DNA in the peripheral blood leukocytes of HIV-infected patients. AIDS (1996) 1.02
Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus. AIDS (1993) 1.02
Preparation and properties of an inhibitory extract from frog virus 3 particles. J Virol (1973) 1.02
Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study. Antivir Ther (1999) 1.01
Production of cytokines in patients infected by hepatitis C virus. J Med Virol (1998) 1.01
Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro. AIDS Res Hum Retroviruses (1997) 1.01
Further ultrastructural observations of virus morphogenesis and myelin pathology in JHM virus encephalomyelitis. Neuropathol Appl Neurobiol (1980) 1.01
CD4+ CCR5+ T-cell dynamics during simian immunodeficiency virus infection of Chinese rhesus macaques. J Virol (2007) 1.00
Permissivity of primary cultures of human Kupffer cells for HIV-1. AIDS Res Hum Retroviruses (1990) 1.00
HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment. AIDS Res Hum Retroviruses (2000) 0.99
Enantiomeric 2',3'-dideoxycytidine derivatives are potent human immunodeficiency virus inhibitors in cell cultures. C R Acad Sci III (1994) 0.99
Effects of corticosteroids on HCV infection. Int J Immunopharmacol (1999) 0.99
Quantitation of HIV-1 RNA in dried blood and plasma spots. J Virol Methods (2009) 0.98
Symptomatic mumps virus reinfections. J Med Virol (1995) 0.98
Specific and non-specific immunity and protection of macaques against SIV infection. Vaccine (1992) 0.97
High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env, rev, tat, and vpu genes from HIV-1 Lai. Virology (1996) 0.97
Studies of trinucleotide conformations. Role of guanine residues in an oligonucleotide chain. Biochemistry (1969) 0.97
Rapid diagnosis of acute mumps infection by a direct immunoglobulin M antibody capture enzyme immunoassay with labeled antigen. J Clin Microbiol (1985) 0.97
Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition. J Virol (2001) 0.97
Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients. AIDS Res Hum Retroviruses (1997) 0.96
In vitro antiviral properties of endotoxin-activated rat Kupffer cells. J Leukoc Biol (1985) 0.96
Fate of frog virus 3 DNA replicated in the nucleus of arginine-deprived CHO cells. J Gen Virol (1984) 0.95
Pandemic influenza A(H1N1) 2009: molecular characterisation and duration of viral shedding in intensive care patients in Bordeaux, south-west France, May 2009 to January 2010. Euro Surveill (2011) 0.95
Structure and regulation of the immediate-early frog virus 3 gene that encodes ICR489. J Virol (1988) 0.94
Persistence of pathogenic challenge virus in macaques protected by simian immunodeficiency virus SIVmacDeltanef. J Virol (2001) 0.93
Localization of viral protein X in simian immunodeficiency virus macaque strain and analysis of its packaging requirements. J Gen Virol (1994) 0.93
In vitro infection of human macrophages with human T-cell leukemia virus type 1. Blood (1993) 0.93
Serum selenium predicts outcome in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.93
Early changes in peripheral blood T cells during primary infection of rhesus macaques with a pathogenic SIV. J Med Primatol (2000) 0.92
The inhibition of vaccinia virus DNA synthesis in KB cells infected with frog virus 3. J Gen Virol (1970) 0.92
Molecular cloning and physical and translational mapping of the frog virus 3 genome. Virology (1988) 0.92
Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA Analysis System to conventional gel based systems for HIV drug resistance analysis. J Virol Methods (2001) 0.92
Penetration and uncoating of frog virus 3 (FV3) in cultured rat Kupffer cells. Virology (1981) 0.92
Effects of morphine on purified human blood monocytes. Modifications of properties involved in antiviral defences. Int J Immunopharmacol (1997) 0.91
JC virus remains latent in peripheral blood B lymphocytes but replicates actively in urine from AIDS patients. J Infect Dis (1998) 0.91
Differing infection patterns of dengue and yellow fever viruses in a human hepatoma cell line. J Infect Dis (1998) 0.91
Qualitative and quantitative molecular detection of enteroviruses in water from bathing areas and from a sewage treatment plant. Res Microbiol (2001) 0.91
HIV type 1 Thai subtype E is predominant in South Vietnam. AIDS Res Hum Retroviruses (1996) 0.91